Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10483955 | 0.75 | CHRM2 (0.40) | SLC40A1CHRM2POLBMEN1KMT2A | |
| SCHEMBL2082216 | 0.73 | CXCR4 (0.36) | — | |
| SCHEMBL23428770 | 0.70 | CXCR4 (0.43) | CHRM2 | |
| SCHEMBL23870975 | 0.70 | SIGMAR1 (0.33) | — | |
| SCHEMBL7995737 | 0.70 | SLC40A1 (0.38) | SLC40A1CHRM2POLBMEN1KMT2A | |
| SCHEMBL30894457 | 0.67 | CHRM2 (0.62) | CHRM2MEN1KMT2A | |
| SCHEMBL20278969 | 0.67 | ALDH1A1 (0.39) | MEN1KMT2A | |
| SCHEMBL28330979 | 0.67 | CD274 (0.43) | SLC40A1CHRM2 | |
| SCHEMBL16269366 | 0.66 | CYP2C19 (0.44) | SLC40A1MEN1KMT2A | |
| SCHEMBL19582432 | 0.65 | SLC40A1 (0.36) | SLC40A1CHRM2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | SLC40A1 1604/4885CHRM2 655/4885POLB 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.